Jennifer's Shared Resources

Sequential NIT Screening for MASH Reduces Biopsies and Costs
This study evaluated the diagnostic performance of non-invasive tests (NITs) like the FibroScan-AST (FAST) score, LSM-VCTE, FIB-4, and NFS for...

Efruxifermin Shows Promise in Treating MASH, Targeting Liver Scarring
Efruxifermin, an experimental drug mimicking fibroblast growth factor 21 (FGF21), is being investigated in phase 3 SYNCHRONY trials for the...

Challenges of Liver Transplantation for MASLD
Liver transplantation (LT) for metabolic dysfunction-associated steatotic liver disease (MASLD) is challenging due to high comorbidity rates, including obesity, diabetes,...

Genetic Risk Factors for NASH-Related Hepatocellular Carcinoma
This study aimed to identify genetic risk factors driving the progression from non-alcoholic fatty liver disease (NAFLD) to non-alcoholic steatohepatitis...

MASH Risk Guide for At-Risk Patients
This guide is designed for patients at risk for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH)....

NASH Becoming Leading Cause for Liver Transplantation
Nonalcoholic steatohepatitis (NASH) is rapidly becoming the leading indication for liver transplantation in the US. However, patients with NASH face...